News
RNA
42.95
-1.62%
-0.71
Insider Sale: Chief Human Resources Officer of $RNA (RNA) Sells 25,000 Shares
Barchart · 1d ago
Analysts Anticipate 10% Gains Ahead For FNX
NASDAQ · 2d ago
Weekly Report: what happened at RNA last week (1111-1115)?
Weekly Report · 3d ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 6d ago
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
NASDAQ · 11/14 19:16
Avidity Biosciences: Expanding Horizons in Precision Cardiology with New Genetic Targets
TipRanks · 11/14 07:45
Avidity Biosciences Is Maintained at Buy by Chardan Capital
Dow Jones · 11/13 23:40
Avidity Biosciences Price Target Maintained With a $65.00/Share by Chardan Capital
Dow Jones · 11/13 23:40
Chardan Capital Maintains Buy on Avidity Biosciences, Maintains $65 Price Target
Benzinga · 11/13 23:30
Avidity Biosciences jumps 16%; reaches all-time high
Seeking Alpha · 11/13 16:40
TD Cowen Reaffirms Their Buy Rating on Avidity Biosciences (RNA)
TipRanks · 11/13 13:08
Assessing Avidity Biosciences: Insights From 10 Financial Analysts
Benzinga · 11/13 13:01
3 Best Stocks to Buy Now, 11/13/2024, According to Top Analysts 
TipRanks · 11/13 11:00
Avidity Biosciences (RNA) Gets a Buy from Barclays
TipRanks · 11/13 10:16
Avidity Biosciences Price Target Maintained With a $60.00/Share by Needham
Dow Jones · 11/13 10:07
Avidity Biosciences’ Strategic Expansion in Precision Cardiology and siRNA Innovation Justifies Buy Rating
TipRanks · 11/13 10:05
Needham Reiterates Buy on Avidity Biosciences, Maintains $60 Price Target
Benzinga · 11/13 09:57
Promising Outlook for Avidity Biosciences: Strategic Focus on Genetic Targeting and Innovative AOC Technology
TipRanks · 11/13 07:35
Buy Rating Affirmed for Avidity Biosciences Amid Precision Cardiology Advancements
TipRanks · 11/12 19:25
Chevron, Super Micro Computer top list of most shorted large-cap stocks in October, Hazeltree says
Seeking Alpha · 11/12 18:26
More
Webull provides a variety of real-time RNA stock news. You can receive the latest news about Avidity Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RNA
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.